Jean-Philippe Theurillat, MD, discusses castration and androgen receptor inhibition in prostate cancer.
Jean-Philippe Theurillat, MD, group leader, Institute of Oncology Research, associate professor, Universita della Svizzera italiana, Lugano, Switzerland, discusses castration and androgen receptor inhibition in prostate cancer.
Surgical or pharmacologic castration has shown marked responses in some men with prostate cancer, Theurillat says.
Additionally, more potent second-generation antiandrogen agents and cytochrome inhibitors can induce prolonged responses for this patient population, explains Theurillat.
Although some patients may have durable responses on these therapies, others may progress after only a few weeks, says Theurillat.
Research suggests that response is largely dependent on genetic driver events, concludes Theurillat.